leadf
logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics continues to move toward commercialization of their testing program for COVID-19

XPhyto Therapeutics (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide an update on their plans to go to market in Europe with their testing program for the COVID-19

Rogers talks about where that program is AT and also about their drug delivery platform which they are looking at expanding as well.

Quick facts: XPhyto Therapeutics Corp.

Price: 2.55 CAD

CSE:XPHY
Market: CSE
Market Cap: $154.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto to take big steps forward in 2021 in diagnostics, drug formulations,...

XPhyto Therapeutics (CSE: XPHY- OTCQB: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide an update on what the company is planning for a very busy 2021. Rogers laying out the plan for three areas of their business. Rogers telling Proactive they expect major steps forward...

11 hours, 2 minutes ago

2 min read